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Abstract
Background: Bladder cancer is the sixth most common cancer in the world and the incidence is particularly high
in southwestern Taiwan. Previous studies have identified several tumor-related genes that are hypermethylated in
bladder cancer; however the DNA methylation profile of bladder cancer in Taiwan is not fully understood.
Methods: In this study, we compared the DNA methylation profile of multiple tumor suppressor genes (APC, DAPK,
E-cadherin, hMLH1, IRF8, p14, p15, RASSF1A, SFRP1 and SOCS-1) in bladder cancer patients from different Chinese
sub-populations including Taiwan (104 cases), Hong Kong (82 cases) and China (24 cases) by MSP. Two normal
human urothelium were also included as control. To investigate the diagnostic potential of using DNA methylation
in non-invasive detection of bladder cancer, degree of methylation of DAPK, IRF8, p14, RASSF1A and SFRP1 was also
accessed by quantitative MSP in urine samples from thirty bladder cancer patients and nineteen non-cancer
controls.
Results: There were distinct DNA methylation epigenotypes among the different sub-populations. Further, samples
from Taiwan and China demonstrated a bimodal distribution suggesting that CpG island methylator phentotype
(CIMP) is presented in bladder cancer. Moreover, the number of methylated genes in samples from Taiwan and
Hong Kong were significantly correlated with histological grade (P < 0.01) and pathological stage (P < 0.01).
Regarding the samples from Taiwan, methylation of SFRP1, IRF8, APC and RASSF1A were significantly associated with
increased tumor grade, stage. Methylation of RASSF1A was associated with tumor recurrence. Patients with
methylation of APC or RASSF1A were also significantly associated with shorter recurrence-free survival. For
methylation detection in voided urine samples of cancer patients, the sensitivity and specificity of using any of the
methylated genes (IRF8, p14 or sFRP1) by qMSP was 86.7% and 94.7%.
Conclusions: Our results indicate that there are distinct methylation epigenotypes among different Chinese sub-
populations. These profiles demonstrate gradual increases with cancer progression. Finally, detection of gene
methylation in voided urine with these distinct DNA methylation markers is more sensitive than urine cytology.
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Bladder cancer is the sixth most common cancer in the
world [1] and tenth most common cancer in Taiwan.
Majority of bladder cancer is comprised of urothelial
carcinoma (UC) (also known as transitional cell carci-
noma, TCC). The incidence of urothelial cancer is parti-
cularly high in southwestern coast of Taiwan [2] thus
suggesting that UC in these areas may have unique car-
cinogenesis pathway. Although the carcinogenesis pro-
cess is unclear so far, accumulation of multiple genetic
and epigenetic alternations leading to the activation of
proto-oncogenes and/or inactivation of tumor-suppres-
sor genes (TSGs) is a common consensus [3-5].
One of the distinctive features of UC is that over 80%
of newly diagnosed cases are non-invasive superficial
lesions; however, 50% of them will recur accompanied
with advanced stage of disease and poor prognosis. UC
patients will then need to have a long-term follow-up
with repeated urine cytology and invasive cystoscopy for
recurrence monitoring. Conventional urine cytology has
been the standard noninvasive method for cancer detec-
tion and disease monitoring; however, the sensitivity of
this method is known to be low, especially for low-grade
UC. Therefore, a more sensitive, non-invasive method
for cancer detection is required.
Epigenetic alteration such as DNA methylation is an
important mechanism in regulating transcription [6].
Gene promoter methylation plays an important role in
normal mammalian development; yet, aberrant promoter
hypermethylation is frequently observed in human can-
cers and displays a non-random tumor specific DNA
methylation pattern [7,8]. It is thus suggested that this
non-random methylation pattern may be related to the
unique signaling pathways that are dysregulated in
response to specific carcinogens exposed in specific
tumor type [9]. Therefore, DNA methylation may be a
promising method for non-invasive cancer detection [10].
We along with others have previously shown that
methylation of multiple tumor suppressor genes can be
observed in bladder cancer patients as well as its corre-
sponding voided urine samples [11-15]. In order to
develop a sensitive epigenetic markers panel for diagno-
sis and prognosis in this locality, a more comprehensive
epigenetic profile of UC in Taiwan is needed.
In this study, we aimed to compare the DNA methyla-
tion profile of mutilple tumor suppressors in bladder
cancer paitents from Taiwan, Hong Kong and China by
methylation specific PCR (MSP). The diagnostic poten-
tial of the genes that were found to be frequently
methylated in samples from Taiwan were further
accessed by quantitative MSP (qMSP). Our result
demonstrated that there were distinct methylation epi-
genotypes in bladder urothelial cancer patients from
different Chinese sub-populations and that methylation
markers may provide a sensitive strategy for non-inva-
sive cancer detection in urine samples.
Methods
Tissue and urine samples
Tissue samples from a total of 104 bladder UC patients
from Chia-Yi Christian Hospital, Taiwan, 82 samples
from Prince of Wales Hospital, Hong Kong and 24 sam-
ples from Forth Hospital of Hebei Medical University,
China were collected. For urine samples, paired voided
urine from thirty bladder cancer patients were collected
retrospectively. In addition, nineteen urine samples from
age- and sex-matched non-cancer controls were also
included. All urine samples were collected from Chia-Yi
Christian Hospital, Taiwan. Urine samples were pro-
cessed for DNA extraction as described previously [11].
All patients were asked to sign the informed consent for
obtaining the specimens. The clinical pathological data
for the tissue and urine samples are summarized in
table 1 and 2 respectively. Tumors were graded and
staged according to the WHO grading [16] and the
AJCC TNM staging system [17] respectively. As a con-
trol, primary culture of normal urothelium from two
individuals (purchased from ScienCell, Carlsbad, CA)
were used in this study. All studies involving human
samples were conformed to the Helsinki Declaration
and approved by the Institutional Review Boards of the
Chia-Yi Christian Hospital and the Clinical Research
Table 1 Summary of clinical-pathological data of tumor
samples
Taiwan
(n = 104)
Hong Kong
(n = 82)
China
(n = 24)
Age
Median 70.5 73 64.5
Range 40 - 92 46 - 92 43 - 80
Gender
Male 84 60 23
Female 20 22 1
Histological Grade
Grade 1 34 16 8
Grade 2 42 41 12
Grade 3 28 25 4
Pathological Stage
Stage Ta 41 38 8
Stage T1 41 21 6
Stage ≥ T2 22 23 10
Relapse
Primary 66 23 ND
Recurrence 38 58 ND
ND: data not available.
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Kong and Hebei Medical University.
Extraction of DNA from paraffin-embedded tissues and
urine samples
DNA was extracted from formalin-fixed, paraffin-
embedded tissues or from voided urine sediment using
Tissue and Cell Genomic DNA Purification Kit (Gene-
mark, Taipei, Taiwan) according to manufacturer proto-
col. H&E-stained sections from each tumor sample were
examined by an experienced pathologist to confirm the
clinicopathological parameters.
Bisulfite modification and Methylation-Specific PCR (MSP)
DNA was bisulfite-modified using EZ DNA Methylation
Kit (ZYMO research, Orange, CA) as described pre-
viously [18]. For MSP reaction, four μlo fb i s u l f i t e - c o n -
verted DNA were amplified in a total volume of 20 μl
containing Platinum Taq DNA polymerase (Invitrogen,
Carlsbad, CA). Primers for the MSP reaction are shown
in table S1 (Additional file 1). CpGenome Universal
Methylated DNA (IVD) (Millipore, Bedford, MA) was
used as positive control for methylation, while human
peripheral lymphocyte DNA amplified by GenomePlex
Complete Whole Genome Amplification Kit (Sigma-
Aldrich, St Louis, MO) was used as a positive control for
unmethylation and water was used as negative control
for PCR. Ten μl of PCR products were loaded onto 10%
non-denaturing polyacrylamide gel. The gel was then
stained with ethidium bromide, and visualized under UV
illumination. Methylated samples are defined as the pre-
sence of methylated PCR products in that samples.
Real-time quantitative methylation-specific PCR (qMSP) in
urine samples
For detection of gene promoter methylation in urine
s a m p l e s ,am o r es e n s i t i v ea n d quantitative real-time
methylation-specific PCR (qMSP) was used as described
[18]. In detail, qMSP reactions were performed using
ABI Stepone real time PCR system (ABI, Foster city,
CA) in a total volume of 20 μlc o n t a i n i n g1 0μlo f2 X
SYBR Green Real-time PCR Master Mix (Toyobo,
Osaka, Japan), 160 nM of each primers and 4 μlo f
bisulphite converted DNA at 95°C for 10 mins, 40 cycles
of 95°C for 15 sec, 60°C for 30 sec, and 72°C for 30 sec.
Primers for qMSP targeting DAPK, IRF8, p14, RASSF1A
and SFRP1 are shown in table S1 (additional file 1). A
region of b-actin, devoid of any CpG dinucleotide was
used to normalize for input DNA using the following
primer pairs: ACTB-forward 5’ TGGTGATGGAGG
AGGTTTAGTAAGT and ACTB-reverse, 5’ AACCAA-
TAAAACCT ACTCCTCCCTTAA. The amount of
methylated DNA was determined by the threshold cycle
number (Ct) for each sample against a standard curve
generated by SSSI-treated DNA-MSP cloned fragment.
The percentage of methylation of a certain gene was cal-
culated as the ratio of amount of methylated gene/
A C T Bi nas a m p l ed i v i d e db yt h es a m er a t i oo fS s s I -
treated sperm DNA and multiplied by 100 [18].
Statistical analysis
Comparison of non-parametric variables was assessed by
Kruskal-Wallis Test or Mann-Whitney test whichever
appropriate. Association between clinical-pathological
parameters was assessed by c
2 or Fisher’s exact test.
Methylation index, MI is defined as the number of
methylation gene divided by the total number of gene
studied in a sample as previously described [19]. MI≥ 5i s
considered as high. Cut-off value for qMSP in urine sam-
ples was determined by ROC curved (Additional file 2:
Figure S1). Recurrence-free survival (RFS) was calculated
from the date of surgery to the date of recurrence or last
follow-up date and assessed by Kaplan-Meier analysis
using log-rank test. All statistical analysis was performed
by SPSS version 13.0 for windows (SPSS, Chicago, IL,
USA). P < 0.05 was considered as significant.
Results
Methylation profile of tumor suppressors in bladder UC
We have analyzed the methylation frequency of multiple
tumor suppressors (APC, DAPK, E-cadherin, hMLH1,
IRF8, p14, p15, RASSF1A, SFRP1 and SOCS-1)t h a ta r e
found to be frequently methylated in various human
cancer including bladder cancer [11,20-25] in primary
Table 2 Summary of clinical-pathological data of urine
samples from tumor patients and normal control in
Taiwan
Cancer
(n = 30)
Normal
(n = 19)
Age
Median 71.5 62
Range 47 - 92 39 - 85
Gender
Male 25 11
Female 5 8
Histological Grade
Grade 1 12
Grade 2 13
Grade 3 5
Pathological Stage*
Stage Ta 13
Stage T1 12
Stage ≥ T2 4
Relapse
Primary 26
Recurrence 4
*Staging information of one cancer patient is not available.
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Page 3 of 11bladder UC tissues from Taiwan (104 cases), Hong Kong
(82 cases) and China (Beijing, 24 cases) by methylation-
specific PCR (Figure 1A). Samples from Taiwan showed
that frequent methylation was detected in p14 (61.8%),
DAPK (51.0%), SFRP1 (47.5%), and IRF8 (46.6%), while
methylation was also detected in APC (41.4%), hMLH1
(37.5%), RASSF1A (32.7%), p15 (24.5%), SOCS-1 (24.0%),
and E-cadherin (21.2%) (Figure 1B). Regarding samples
from Hong Kong, frequent methylation of E-cadherin
(65.9%), DAPK (58.5%), SFRP1 (44.0%), and hMLH1
(42.2%) were detected. Moreover, frequent methylation
of p14 (87.5%), hMLH1 (79.2%), DAPK (54.2%), APC
(45.8%), and E-cadherin (40.9%) were detected in sam-
ples from China (Figure 2A).
Notably, none of these genes showed any aberrant
hypermethylation in normal control as demonstrated in
this study (Additional file 3: Figure S2) and previously
[11] thus suggesting it is tumor specific event.
Distinct DNA methylation epigenotypes in bladder cancer
patients from different Chinese sub-populations
Compared with different Chinese sub-populations, there
were different methylation frequency among samples
from Taiwan, Hong Kong and China (Figure 2). Signifi-
cant differences between methylation of APC, E-cad-
herin, hMLH1, IRF8, p14 and SOCS-1 were found
(Figure 2A). Interestingly, samples from Taiwan dis-
played a bimodal distribution in terms of number of
methylated genes which is the characteristic of CpG
island methylation phenotype, CIMP [26-28] (Figure
2B). However, such phenomenon was not observed in
samples from Hong Kong. Although samples from
China also displayed such bimodal distribution, the
potential biased from the relatively small sample size
from this locality cannot be excluded. Additionally, in
light of the fraction of methylated genes or methylation
index (MI) in a sample, two methylation groups could
be observed: MI-high and MI-low groups (Figure 2C).
MI-high groups displayed a similar pattern regardless of
sample locality, yet MI-low group exhibited a locality-
specific methylation pattern. Taken together, these data
suggest that CIMP may exist in bladder cancer samples
at least in samples from Taiwan and that there are dis-
tinct DNA methylation epigenotypes among samples
from Taiwan, Hong Kong and China.
Gene methylation gradual increases with cancer
progression
To investigate the relationship between DNA methyla-
tion and tumor progression, we analyzed the methylation
index (MI) of the samples with reference to clinical-
pathological parameters. Regarding samples from Tai-
wan, high histological grade and pathological stage was
significantly associated with higher MI (grade, P < 0.01;
stage, P < 0.05; Figure 3A). However, tumor recurrence
was not associated with MI. Samples with high MI were
also significantly associated with higher grade and stage
(P < 0.001) (Table 3). Similar tendencies could also be
observed in samples from Hong Kong (grade, P < 0.05;
Figure 3A, Additional file 4: Table S2). However, such
correlation was not observed in samples from China
w h e r es a m p l es i z ew a sr e l a t i v e ly small (Figure 3, Additional
f i l e4 :T a b l eS 2 ) .B e s i d e s ,w eh a v ea l s oa n a l y z e dt h e
association between methylation of individual genes and
tumor progression. Methylation of SFRP1, IRF8, APC and
RASSF1A were significantly associated with increased
tumor grade and stage in samples from Taiwan (Figure 3B).
Methylation of RASSF1A was also associated with tumor
recurrence (Figure 3B and Table 4). Besides, significant
association between increased tumor grade, stage or
tumor recurrence and methylation of p14, SFRP1, APC,
hMLH1 and p15 were observed in samples from Hong
Kong. Surprisingly, methylation of p14 and APC were
inversely correlated with tumor recurrence (Figure 3B).
In summary, consistent with previous findings, our
results suggest that DNA methylation increases gradually
with tumor progression [29,30].
Figure 1 Methylation analysis of APC, DAPK, E-cadherin, hMLH1,
IRF8, p14, p15, RASSF1A, SOCS-1 and SFRP1 in tumor tissues of
bladder cancer patients by MSP. A. Representative gel
electrophoresis images of the MSP result from Taiwan bladder
cancer samples TW262 and TW20. M indicates the presence of
methylated genes; U indicates the presence of unmethylated genes.
IVD (in vitro methylated DNA) was used as the positive control for
methylation; Normal blood (NB) genomic DNA was used as the
positive control for unmethylation; B. Frequency of methylation of
different genes in tumor tissues from 104 Taiwan bladder cancer
patients.
Chen et al. BMC Medical Genomics 2011, 4:45
http://www.biomedcentral.com/1755-8794/4/45
Page 4 of 11Figure 2 DNA Methylation profiles from different Chinese sub-populations. A. The histogram showed that methylation of p14, IRF8, APC,
hMLH1, SOCS-1 and E-cadherin varied among different Chinese sub-populations. * and ** denote P < 0.05 and P < 0.01 respectively (Mann-
Whitney U). B, Histogram showing the number of patients against the number of genes methylated concurrently. Samples from Taiwan and
China displayed bimodal distribution which is a characteristic of CpG island methylator phentotype (CIMP). C. Dichotomous heat map of the
DNA methylation data from different Chinese sub-populations. Black, orange and blue blocks represented methylated loci from Taiwan, Hong
Kong and China respectively. Red bars indicated MI-high populations (≥5 genes showing concurrent methylation) and green bars indicated MI-
low populations.
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Page 5 of 11Figure 3 Association between gene methylation and tumor progression of bladder cancer in different Chinese sub-populations.T h e
histogram demonstrated the association between (A) methylation index, MI or (B) methylation of individual gene with tumor progression in
terms of tumor grade, stage and relapse in bladder cancer samples from Taiwan, Hong Kong (HK) and China. Low grade represented grade 1
cases; high grade represented ≥ grade 2 cases. Low stage represented stage < T2 cases; high stage represented ≥ T2 cases. * and **, P < 0.05
and P < 0.01 respectively.
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Page 6 of 11Methylation of APC and RASSF1A predict recurrence free
survival in bladder cancer patients
Recurrence is a common clinical manifestation in blad-
der UC, thus development of a relapse indicator will be
important for cancer monitoring. We investigated the
correlation between methylation of the analyzed markers
and recurrence-free survival (RFS) of bladder cancer
patients by Kaplan-Meier analysis. Since MI did not
show any correlation with RFS in our samples, we pro-
ceeded to analyze such correlation with individual
methylation markers. Out of the 10 methylation makers,
patients in Taiwan with methylation of APC (P = 0.0146)
or RASSF1A (P = 0.0376) demonstrated a shorter RFS
than those without methylation (Figure 4).
DNA methylation markers in voided urine as cancer
detection tool
In order to assess the feasibility of using DNA methyla-
tion as a biomarker for cancer detection and recurrence
monitoring, genes showing highest methylation fre-
quency (p14, DAPK, SFRP1,a n dIRF8) in tumor tissues
from Taiwan samples and RASSF1A which have been
previously found to be methylated in bladder cancer
patients [12,22,31] were selected as potential targets for
methylation detection in urine samples that were
acquired retrospectively from a different patient pool
from Taiwan. Voided urine from thirty bladder UC
patients were analyzed by a more sensitive quantitative
MSP (qMSP) assay for methylation detection [32,33].
Nineteen samples from non-cancer patients in the same
locality were also included as control (Table 2). As com-
pare to non-cancer group, higher methylation level of
DAPK, IRF8, p14, RASSF1A and SFRP1 were detected in
cancer samples (Figure 5). We then performed receiver
operating characteristic (ROC) curve to determine an
optimal cut-off values for each gene (Additional File 2:
Figure S1). Based on these cut-off values, the sensitivity
of our qMSP assay using DAPK, IRF8, p14, RASSF1A
Table 3 Correlations between methylation index and
clinical-pathological data in Taiwan samples
MI - High
1 MI - Low
Mean ± SD
Age 70.4 ± 12.7 68.4 ± 11.8
No. of cases P
Gender
Male 36 48 0.295
Female 6 14
Histological Grade
Grade 1 5 29
Grade 2 16 26 <0.001
Grade 3 21 7
Pathological Stage
Stage Ta 9 32
Stage T1 17 24 <0.001
Stage ≥ T2 16 6
Relapse
Primary 24 42 0.273
Recurrence 18 20
1 Cases grouped into MI-High if methylation index ≥ 5; otherwise, grouped
into MI-Low.
Table 4 Correlation between RASSF1A methylation and
cancer recurrence in Taiwan samples
RASSF1A
Methylated unmethylated P
Primary (n = 66) 17 (25.7%)
1 49 (74.2%)
Recurrence (n = 38) 17 (44.7%) 21 (55.2%) 0.039
1Values are number of cases (%).
Figure 4 Kaplan-Meier analysis of APC or RASSF1A methylation
for recurrence-free survival (RFS) in bladder cancer patients
from Taiwan. Patients were grouped according to methylation of
(A) APC or (B) RASSF1A as determined by MSP. Patients with
methylation of APC or RASSF1A have a significant shorter time of
RFS. P-values from Gehan-Breslow-Wilcoxon test are shown.
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Page 7 of 11and SFRP1 was 26.7%, 56.7%, 27.6%, 30.0% and 41.4%
respectively; and the specificity was 89.5%, 94.7%, 100%,
89.5% and 100% respectively (Table 5). By combining
IRF8, p14 and SFRP1 together as a panel of methylation
markers, the sensitivity and specificity of a sample show-
ing methylation of one of these 3 genes was 86.7% and
94.7%, respectively (Table 5). Notably, the sensitivity of
this markers panel for grade 1 and recurrent tumors
was 91.7% and 100% respectively. Additionally, we have
also analyzed the correlation between RFS and methyla-
tion of individual markers (or markers panel) in these
thirty urine samples. However, probably due to small
sample size, no significant difference can be found. A
more detail methylation analysis on urine samples can
also be found in table S3 (Additional file 5).
Discussion
Aberrant promoter methylation is a hallmark of cancer.
In this study, we analyzed the methylation profiles of ten
tumor suppressors that are frequently methylated in var-
ious human cancers [11,20-25] in bladder UC from dif-
ferent Chinese sub-populations. Our results showed that
93.3%, 95.2% and 100% of patients from Taiwan, Hong
Kong and China, respectively, had at least one gene
methylated thus suggesting that epigenetic event of gene
methylation is frequent in bladder cancer. Although none
Figure 5 Quantification of DAPK, IRF8, p14, RASSF1A and SFRP1 methylation in voided urine samples from bladder cancer patients
from Taiwan by qMSP. Values in dot plot represented methylation percentage relative to the IVD (100%). The horizontal line represented
median value. ** denotes P < 0.01 (Mann-Whitney U).
Table 5 Sensitivity and specificity of cancer detection using voided urine samples from Taiwan
DAPK IRF8 p14 RASSF1A SFRP1 Methylation markers
1
Sensitivity (%)
All cases(n = 30) 26.7 56.7 27.6 30.0 41.4 86.7
Grade 1(n = 12) 25.0 50.0 41.7 16.7 50.0 91.7
Grade 2-3(n = 18) 27.7 61.1 16.7 38.9 33.4 83.3
Primary (n = 26) 30.8 61.5 30.8 30.8 34.6 84.6
Recurrence (n = 4) 0 25 0 25 75 100
Specificity (%)(n = 19) 89.5 94.7 100 89.5 100 94.7
1 Any one of these genes (IRF8, p14 and sFRP1) showed methylation in urine samples.
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Page 8 of 11of these genes showed any aberrant hypermethylation in
primary culture of normal urothelium from two indivi-
duals, more control samples may be needed for further
validation. On the other hand, methylation of the ana-
lyzed genes in patients from Hong Kong and/or China
showed an obvious diversity as compared to that from
Taiwan; for example, IRF8 showed higher frequency of
methylation in samples from Taiwan (46.6%) than from
Hong Kong (27.6%) and China (25.0%). However, the
result from China patients may need to further validate
by increasing the sample size. Nevertheless, these differ-
ences may be attributed to genetic or environmental dif-
ferences in these localities as differences in sex, age, stage
and grade cannot explain this methylation diversity.
Exposure to environmental carcinogen and uptake of
different diets has been shown to be the major reasons
causing such distinct DNA methylation epigenotypes
[34,35]. In Taiwan, bladder cancer is particularly com-
mon in endemic areas of arsenic-induced Blackfoot dis-
ease. Previous studies have demonstrated that arsenic
pollution is associated with DAPK and RASSF1A methy-
lation in bladder cancer [36,37]. It may be one of the fac-
tors that contribute to this distinct methylation
epigenotype. However, our result demonstrated a similar
methylation level of DAPK and RASSF1A in samples
from different Chinese sub-populations. It may result
from the fact that arsenic exposure from artesian well
water has decreased in arsenious-endemic area due to
the improvement of drinking water system [38]. How-
ever, similar effect from different carcinogens in different
localities cannot be excluded. Besides, it has also been
reported that influences of dietary factors interact with
DNA methylation in colorectal cancer [39]. Thus, differ-
ent environmental factors together with genetic factors
may contribute to these distinct methylation profiles.
In the current study, samples from Taiwan and China
displayed a strongly bimodal distribution by the number
of methylated genes, which implied that CIMP may
exist in bladder UC [36]. However samples from Hong
Kong did not exhibit such typical CIMP methylation
pattern. This may be due to the fact that genes that we
analyzed are not suitable for CIMP analysis in samples
from Hong Kong, thus suggesting that the carcinogen-
esis in bladder UC in Hong Kong may be different from
Taiwan and China fundamentally.
In keeping with previous observation [19,29], our
study also demonstrated that methylation of several
genes such as APC and RASSF1A were associated with
tumor progression. Methylation of RASSF1A was also
associated with tumor recurrence. However, the inverse
correlation between methylation of p14 and APC with
tumor recurrence needs to be further validated.
DNA methylation has been previously demonstrated
to be able to predict patient’s survival and recurrence
[19,29,40]. In the current study, patients from Taiwan
with methylation in APC or RASSF1A tended to have a
shorter RFS. The absence of such correlations in sam-
ples from other Chinese sub-populations may be due to
similar reasons as discussed above. Previous studies
have indicated that bladder cancer patients with APC or
RASSF1A methylation show a trend toward poor survi-
val [19,29]. Furthermore, loss of E-cadherin expression
had been reported to be associated with increased risk
of recurrence in bladder cancer [41]. Although Mura-
maki et al did not investigate the role of DNA methyla-
tion in their study, loss of E-cadherin expression may
result from aberrant promoter methylation. Our results
also demonstrated a similar trend that the primary blad-
d e rU Cp a t i e n t sw i t hE-cadherin methylation had a
shorter time of RFS (median = 6.1 months versus 10.9
months, P = 0.07).
Due to the high recurrence rate of bladder UC, patients
usually need to have repeated cystoscopy for disease moni-
toring thus promoting the development of non-invasive
strategies. With the advances of cancer epigenetics, detec-
tion of methylated genes in voided urine becomes feasible
as previously demonstrated [11,14,15,23,42]. In this study,
we utilized a more sensitive quantitative real-time MSP
assay (qMSP) for cancer detection in voided urine samples
using a combination of methylated markers. Methylation
can be detected in low grade samples with high sensitivity.
Importantly, methylation can be detected in all of the
urine samples from patients with recurrent tumors. How-
ever, more samples and specific methylation markers
should be included for further validation and improve the
diagnostic accuracy. By combining urine cytology with
methylation markers and other protein biomarkers such
as NMP22 [43], the sensitivity of cancer detection can also
be dramatically increased.
Conclusions
Our study demonstrated that there were distinct DNA
methylation epigenotypes in bladder cancer samples
from different Chinese sub-populations. Detection of
methylated genes in voided urine, as a potential non-
invasive diagnostic tool, deserves further investigation.
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Additional file 1: Table S1: Primer sequences, annealing
temperatures and product size for MSP
Additional file 2: Figure S1: ROC curve of DAPK, IRF8, p14, RASSF1A,
and SFRP1 methylation. Receiver-operator characteristic (ROC) curve of
the DAPK, IRF8, p14, RASSF1A, and SFRP1 methylation based on qMSP
result. The Cut-off value and the corresponding sensitivity and specificity
for each gene is also shown.
Additional file 3: Figure S2: MSP gel image of the studied tumor
suppressors in normal human normal urothelium (HUC) from two
individuals. Methylation analysis of APC, DAPK, E-cadherin, hMLH1, IRF8,
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Page 9 of 11p14, p15, RASSF1A, SOCS-1 and SFRP1 in normal human normal
urothelium (HUC) from two individuals. M indicates the presence of
methylated genes; U indicates the presence of unmethylated genes. IVD
(in vitro methylated DNA) was used as the positive control for
methylation and water (H2O) was used as a negative control for PCR.
Additional file 4: Table S2: Correlations between methylation index
and clinical-pathological parameters in bladder cancer samples of
different Chinese sub-population
Additional file 5: Table S3: Summary of qMSP analysis of voided
urine samples from Taiwan
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